Skip to main content

Table 1 Patient, tumor, and treatment-related characteristics of thymic tumor (n = 156)

From: Nomogram predict relapse-free survival of patients with thymic epithelial tumors after surgery

Characteristic Training Cohort(n = 116) Validation Cohort(n = 40)
N % N %
Gender
 Male 63 54.3 20 50.0
 Female 53 45.7 20 50.0
Age (years)
  ≤ 60 89 76.7 32 80.0
 >60 27 23.3 8 20.0
Smoking history
 Never 84 72.4 34 85.0
 Ever 32 27.6 6 15.0
Drinking history
 No 100 86.2 37 92.5
 Yes 16 13.8 3 7.5
Family history of tumor
 No 98 84.5 34 85.0
 Yes 18 15.5 6 15.0
Underlying diseases
 No 82 70.7 34 85.0
 Yes 34 29.3 6 15.0
Tumor size (cm)
  ≤ 6 65 56.0 24 60.0
 >6 51 44.0 16 40.0
pT stage
 T1 91 78.4 31 77.5
 T2–3 25 21.6 9 22.5
Masaoka stage
 I 61 52.6 15 37.5
 II-III 55 47.4 25 62.5
WHO stage
 A-AB 45 38.8 18 45.0
 B1-B3 60 51.7 17 42.5
 C 11 9.5 5 12.5
Myasthenia gravis,
 No 107 92.2 37 92.5
 Yes 9 7.8 3 7.5
tumor capsule status
 Incomplete 38 32.8 9 22.5
 Complete 78 67.2 31 77.5
Invasion of great vessels
 No 91 78.4 33 82.5
 Yes 25 21.6 7 17.5
ALB
  ≤ 40.8 29 25.0 7 17.5
 >40.8 87 75.0 33 82.5
GLB
  ≤ 28.8 58 50.0 6 15.0
 >28.8 58 50.0 34 85.0
A/G
  ≤ 1.5 54 46.6 18 45.0
 >1.5 62 53.4 22 55.0
NE
  ≤ 5.6 102 87.9 32 80.0
 >5.6 14 12.1 8 20.0
LY
  ≤ 2.5 28 24.1 8 20.0
 >2.5 88 75.9 32 80.0
NE/LY (NLR)
  ≤ 3.0 100 86.2 32 80.0
 >3.0 16 13.8 8 20.0
PLT
  ≤ 237 64 55.2 16 40.0
 >237 52 44.8 24 60.0
PLT/LY (PLR)
  ≤ 161.6 104 89.7 32 80.0
 >161.6 12 10.3 8 20.0
PLT/NE*LY (SII)
  ≤ 764.3 102 87.9 30 75.0
 >764.3 14 12.1 10 25.0
  1. NLR neutrophil-to-lymphocyte ratio, Hb hemoglobin, ALB albumin, BMI body mass index, NE neutrophil count, LY lymphocyte count, GLB globulin, SII systemic immune-inflammation Index, PLT platelet, PLR platelet-lymphocyte ratio, pT stage pathological T stage